Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects.. Vaccine, 33(39), 5225-34. presented at the 2015 Sep 22. doi:10.1016/j.vaccine.2015.06.075. (2015).
Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons. J Infect Dis, 206(6), 811-20. presented at the 2012 Sep 15. doi:10.1093/infdis/jis427. (2012).
Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial. JAMA, 312(14), 1420-8. presented at the 2014 Oct 08. doi:10.1001/jama.2014.12609. (2014).
Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Volunteers: a Randomized, Placebo-Controlled First-in-Human Single-Dose Escalation Study. Antimicrob Agents Chemother, 63(4). presented at the 2019 04. doi:10.1128/AAC.02255-18. (2019).
Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Adults in an Open Label Phase 1 Multiple Ascending Dose and Food Effect Study. Antimicrob Agents Chemother. presented at the 2020 Aug 17. doi:10.1128/AAC.01018-20. (2020).
Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.. Vaccine, 36(5), 606-614. presented at the 2018 01 29. doi:10.1016/j.vaccine.2017.12.061. (2018).
A randomized, placebo-controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with end-stage renal disease immunized prior to renal transplantation. Transpl Infect Dis, 20(3), e12874. presented at the 2018 Jun. doi:10.1111/tid.12874. (2018).
Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine, 27(37), 5091-5. presented at the 2009 Aug 13. doi:10.1016/j.vaccine.2009.06.057. (2009).
Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age. J Pediatric Infect Dis Soc, 4(3), 214-24. presented at the 2015 Sep. doi:10.1093/jpids/piu061. (2015).
Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial. PLoS One, 14(9), e0222178. presented at the 2019. doi:10.1371/journal.pone.0222178. (2019).
Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women. Vaccine, 36(52), 8054-8061. presented at the 2018 12 18. doi:10.1016/j.vaccine.2018.10.088. (2018).
Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules. Pediatrics, 137(2), e20152603. presented at the 2016 Feb. doi:10.1542/peds.2015-2603. (2016).
Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. JAMA, 312(14), 1409-19. presented at the 2014 Oct 08. doi:10.1001/jama.2014.12854. (2014).